Bionano Genomics, Inc. (NASDAQ:BNGO) Shares Shorted: Short Interest Up 77.9% in September

Bionano Genomics, Inc. (NASDAQ:BNGO) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 2,035,020 shares, a growth of 77.9% from the September 15th total of 1,144,194 shares. Based on an average daily volume of 978,648 shares, the short-interest ratio is presently 2.1 days. Currently, 17.4% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Bionano Genomics stock. GSA Capital Partners LLP bought a new stake in Bionano Genomics, Inc. (NASDAQ:BNGO) during the second quarter, according to its most recent filing with the SEC. The firm bought 150,284 shares of the company’s stock, valued at approximately $170,000. GSA Capital Partners LLP owned about 1.31% of Bionano Genomics at the end of the most recent quarter. Hedge funds and other institutional investors own 11.35% of the company’s stock.

Bionano Genomics Price Performance

Shares of Bionano Genomics stock remained flat at $1.37 during trading on Thursday. The stock had a trading volume of 10,787 shares, compared to its average volume of 463,976. Bionano Genomics has a twelve month low of $1.00 and a twelve month high of $2.23. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.96 and a current ratio of 2.48. The firm’s fifty day simple moving average is $1.37 and its two-hundred day simple moving average is $1.25. The stock has a market capitalization of $16.13 million, a price-to-earnings ratio of -0.45 and a beta of 1.66.

Bionano Genomics (NASDAQ:BNGO) last released its earnings results on Monday, August 10th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.03. The business had revenue of ($6.67) million for the quarter, compared to the consensus estimate of $7.55 million. Bionano Genomics had a negative net margin of 106.58% and a negative return on equity of 78.78%. As a group, research analysts forecast that Bionano Genomics will post -2.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on BNGO shares. Weiss Ratings raised Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. Wall Street Zen upgraded Bionano Genomics to a “hold” rating in a research report on Saturday, September 26th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $6.00.

Bionano Genomics Company Profile

Bionano Genomics, Inc is a life sciences company that develops genomic analysis solutions based on optical genome mapping (OGM). Its technology is designed to identify structural variations and other genomic abnormalities that may be difficult to detect with traditional sequencing and cytogenetic methods.

The company’s principal platform is the Saphyr system, which includes instrumentation, consumables and software for analyzing ultra-long DNA molecules. Bionano also provides data-analysis tools and informatics solutions intended to support research and clinical workflows in areas such as constitutional genetics, oncology and hematologic malignancies.

Bionano Genomics serves academic, government, pharmaceutical and biotechnology researchers, as well as clinical laboratories in the United States and international markets.